Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that affected investors between October 31, 2024, and April 30, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding its debt reduction strategy after acquiring Dermavant [2] - Following the revelation of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Financial Data and Key Metrics Changes - In 2024, Organon reported full year revenue of $6.4 billion, representing a 3% growth at constant currency, marking consecutive years of constant currency revenue growth across all three franchises [27][28] - The company generated $967 million in free cash flow before one-time costs, aligning with expectations, and improved adjusted EBITDA margin year over year excluding IPR&D [28] Business Line Data and Key Metrics Changes - The women's health franchise grew by 5% year over year at constant currency, driven by strong double-digit performance of Nexplanon, which is on track to exceed $1 billion in 2025 [29] - The biosimilars franchise delivered 12% growth at constant currency, with HEDLEMA being a leading biosimilar by total prescriptions in the US [30] - Established brands grew by 2% year over year at constant currency, marking consecutive years of growth for this franchise [30] Market Data and Key Metrics Changes - The company is navigating the loss of exclusivity for one of its largest products, Adazed, in Europe, which is expected to impact revenue in 2025 [35] - The revenue growth profile is anticipated to be in the low to mid single-digit range on a constant currency basis over the medium term [35] Company Strategy and Development Direction - Organon is focused on delivering long-term shareholder value through a diversified global portfolio and has prioritized capital allocation to reduce debt faster [32] - The company aims to enhance its revenue growth profile through strategic acquisitions and investments in innovation, particularly in women's health [32][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and its ability to weather a volatile macroeconomic environment, emphasizing the importance of deleveraging and improving margins [36][38] - The commitment to women's health remains strong, with ongoing investments in areas of high unmet need, such as endometriosis and migraine treatments [39][40] Other Important Information - The board of directors recommended against a shareholder proposal for a director election resignation guideline, citing existing governance practices [17][22] - The preliminary vote report indicated that 20.9% of total votes cast supported the shareholder proposal, which did not achieve the majority required for approval [22] Q&A Session Summary Question: When can we expect Organon to return to growth? - Management indicated that growth is expected to resume post-2025 as the company navigates the loss of exclusivity for Adazed and anticipates continued uptake in VITAMMA and growth in the biosimilars business [35] Question: What drove the company's recent decision to reduce its dividend payout? - The decision was part of a reset in capital allocation priorities aimed at accelerating deleveraging to strengthen the company's financial position [36] Question: Can Organon improve its margins? Are there opportunities to reduce organizational costs? - Management confirmed a focus on optimizing the cost structure, targeting $200 million in cost savings for 2025, which is expected to annualize to approximately $275 million in 2026 and beyond [37][38] Question: How committed is Organon to its vision of being a leader in women's health? - The company remains committed to improving women's health, emphasizing its unique focus in this area and ongoing investments in relevant therapeutic areas [39][40] Question: How does current executive compensation align with financial results? - Executive compensation is closely tied to performance, with a significant portion being variable and based on measurable outcomes, ensuring alignment with shareholder interests [42][44]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Organon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Organon securities during the Class Period have until July 22, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance - On May 1, 2025, Organon reported a significant reduction in its dividend payout from $0.28 to $0.02, indicating a shift in capital allocation priorities [4]. - Following the announcement of the dividend cut, Organon's stock price dropped by $3.48 per share, or 26.91%, closing at $9.45 per share on the same day [4].

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentation regarding its capital allocation priorities and dividend payouts following its acquisition of Dermavant [1][3][4]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - Following the acquisition, Organon allegedly shifted its capital allocation focus to debt reduction, contrary to its previous assurances [3]. Dividend Changes - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, citing a reset of capital allocation priorities to prioritize deleveraging [4]. - This announcement led to a decline in Organon's stock price by $3.48 per share, approximately 27%, from $12.93 to $9.45 on the following day [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Group 1: Allegations and Impact - The allegations state that Organon provided overly positive statements to investors while concealing adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a significant decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation for participation [4]. Group 3: Law Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][2]. Allegations - The complaint alleges that Organon's management provided overly positive statements while concealing the prioritization of debt reduction following the acquisition of Dermavant, which led to a significant reduction in the quarterly dividend by 70% [1]. - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from October 31, 2024, to April 30, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for July 22, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices, aiming to ensure companies adhere to responsible business practices [3].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant cut in its dividend [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Organon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until July 22, 2025, to request to be appointed as Lead Plaintiff if they purchased Organon securities during the Class Period [2]. Group 2: Financial Performance - On May 1, 2025, Organon reported a significant reduction in its dividend payout from $0.28 to $0.02, which was attributed to a strategic decision to prioritize capital allocation towards deleveraging [3]. - Following the announcement of the dividend cut, Organon's stock price dropped by $3.48 per share, or 26.91%, closing at $9.45 per share on the same day [3].